248 related articles for article (PubMed ID: 32776237)
1. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme.
Xin Y; Davies A; Briggs A; McCombie L; Messow CM; Grieve E; Leslie WS; Taylor R; Lean MEJ
Diabetologia; 2020 Oct; 63(10):2112-2122. PubMed ID: 32776237
[TBL] [Abstract][Full Text] [Related]
2. Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial.
Xin Y; Davies A; McCombie L; Briggs A; Messow CM; Grieve E; Leslie WS; Taylor R; Lean MEJ
Diabet Med; 2019 Aug; 36(8):1003-1012. PubMed ID: 31026353
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.
Pollock RF; Muduma G; Valentine WJ
Diabetes Obes Metab; 2013 Feb; 15(2):121-9. PubMed ID: 22882321
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
6. Health and Economic Impacts of the National Menu Calorie Labeling Law in the United States: A Microsimulation Study.
Liu J; Mozaffarian D; Sy S; Lee Y; Wilde PE; Abrahams-Gessel S; Gaziano T; Micha R;
Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006313. PubMed ID: 32493057
[TBL] [Abstract][Full Text] [Related]
7. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.
Leslie WS; Ford I; Sattar N; Hollingsworth KG; Adamson A; Sniehotta FF; McCombie L; Brosnahan N; Ross H; Mathers JC; Peters C; Thom G; Barnes A; Kean S; McIlvenna Y; Rodrigues A; Rehackova L; Zhyzhneuskaya S; Taylor R; Lean ME
BMC Fam Pract; 2016 Feb; 17():20. PubMed ID: 26879684
[TBL] [Abstract][Full Text] [Related]
8. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.
Gillett M; Dallosso HM; Dixon S; Brennan A; Carey ME; Campbell MJ; Heller S; Khunti K; Skinner TC; Davies MJ
BMJ; 2010 Aug; 341():c4093. PubMed ID: 20729270
[TBL] [Abstract][Full Text] [Related]
9. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
[TBL] [Abstract][Full Text] [Related]
12. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.
Lean MEJ; Leslie WS; Barnes AC; Brosnahan N; Thom G; McCombie L; Peters C; Zhyzhneuskaya S; Al-Mrabeh A; Hollingsworth KG; Rodrigues AM; Rehackova L; Adamson AJ; Sniehotta FF; Mathers JC; Ross HM; McIlvenna Y; Welsh P; Kean S; Ford I; McConnachie A; Messow CM; Sattar N; Taylor R
Lancet Diabetes Endocrinol; 2019 May; 7(5):344-355. PubMed ID: 30852132
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of professional-mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GP-OSMOTIC trial.
Hua X; Catchpool M; Clarke P; Blackberry I; Chiang J; Holmes-Truscott E; Jenkins A; Khunti K; O'Neal D; Speight J; Furler J; Manski-Nankervis JA; Dalziel K;
Diabet Med; 2022 Mar; 39(3):e14747. PubMed ID: 34806780
[TBL] [Abstract][Full Text] [Related]
17. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of a community-delivered multicomponent intervention compared with enhanced standard care of obese adolescents: cost-utility analysis alongside a randomised controlled trial (the HELP trial).
Panca M; Christie D; Cole TJ; Costa S; Gregson J; Holt R; Hudson LD; Kessel AS; Kinra S; Mathiot A; Nazareth I; Wataranan J; Wong ICK; Viner RM; Morris S
BMJ Open; 2018 Feb; 8(2):e018640. PubMed ID: 29449292
[TBL] [Abstract][Full Text] [Related]
19. Estimation of HbA
Pidd K; Breeze P; Pollard D; Ahern A; Mueller J; Brennan A
Lancet; 2023 Nov; 402 Suppl 1():S75. PubMed ID: 37997120
[TBL] [Abstract][Full Text] [Related]
20. Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
Barnett AH; Arnoldini S; Hunt B; Subramanian G; Hoxer CS
Diabetes Obes Metab; 2018 Aug; 20(8):1921-1927. PubMed ID: 29652101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
